Voyager Therapeutics (VYGR) Competitors $7.00 +0.17 (+2.49%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends VYGR vs. ADVM, JNCE, CASI, BLUE, AGTC, SPRY, SYRE, ARDX, KURA, and TVTXShould you be buying Voyager Therapeutics stock or one of its competitors? The main competitors of Voyager Therapeutics include Adverum Biotechnologies (ADVM), Jounce Therapeutics (JNCE), CASI Pharmaceuticals (CASI), bluebird bio (BLUE), Applied Genetic Technologies (AGTC), ARS Pharmaceuticals (SPRY), Spyre Therapeutics (SYRE), Ardelyx (ARDX), Kura Oncology (KURA), and Travere Therapeutics (TVTX). These companies are all part of the "medical" sector. Voyager Therapeutics vs. Adverum Biotechnologies Jounce Therapeutics CASI Pharmaceuticals bluebird bio Applied Genetic Technologies ARS Pharmaceuticals Spyre Therapeutics Ardelyx Kura Oncology Travere Therapeutics Adverum Biotechnologies (NASDAQ:ADVM) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability. Which has higher earnings and valuation, ADVM or VYGR? Voyager Therapeutics has higher revenue and earnings than Adverum Biotechnologies. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdverum Biotechnologies$3.60M42.81-$117.17M-$7.99-0.93Voyager Therapeutics$250.01M1.53$132.33M$0.2825.00 Do analysts rate ADVM or VYGR? Adverum Biotechnologies presently has a consensus target price of $28.17, indicating a potential upside of 280.12%. Voyager Therapeutics has a consensus target price of $17.43, indicating a potential upside of 148.98%. Given Adverum Biotechnologies' higher probable upside, equities research analysts clearly believe Adverum Biotechnologies is more favorable than Voyager Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adverum Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Voyager Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media refer more to ADVM or VYGR? In the previous week, Voyager Therapeutics had 7 more articles in the media than Adverum Biotechnologies. MarketBeat recorded 9 mentions for Voyager Therapeutics and 2 mentions for Adverum Biotechnologies. Adverum Biotechnologies' average media sentiment score of 1.29 beat Voyager Therapeutics' score of 0.36 indicating that Adverum Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adverum Biotechnologies 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Voyager Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, ADVM or VYGR? Adverum Biotechnologies has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Does the MarketBeat Community favor ADVM or VYGR? Voyager Therapeutics received 19 more outperform votes than Adverum Biotechnologies when rated by MarketBeat users. Likewise, 67.54% of users gave Voyager Therapeutics an outperform vote while only 60.63% of users gave Adverum Biotechnologies an outperform vote. CompanyUnderperformOutperformAdverum BiotechnologiesOutperform Votes36860.63% Underperform Votes23939.37% Voyager TherapeuticsOutperform Votes38767.54% Underperform Votes18632.46% Is ADVM or VYGR more profitable? Voyager Therapeutics has a net margin of 6.28% compared to Adverum Biotechnologies' net margin of 0.00%. Voyager Therapeutics' return on equity of 3.31% beat Adverum Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Adverum BiotechnologiesN/A -74.45% -44.81% Voyager Therapeutics 6.28%3.31%2.33% Do institutionals & insiders have more ownership in ADVM or VYGR? 48.2% of Adverum Biotechnologies shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 4.2% of Adverum Biotechnologies shares are owned by company insiders. Comparatively, 4.5% of Voyager Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryVoyager Therapeutics beats Adverum Biotechnologies on 14 of the 19 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Voyager Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VYGR vs. The Competition Export to ExcelMetricVoyager TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$381.71M$3.16B$5.40B$8.53BDividend YieldN/A1.77%5.13%4.14%P/E Ratio25.0012.18115.5615.18Price / Sales1.53332.351,484.3492.77Price / Cash2.26148.6339.6634.07Price / Book1.304.024.665.02Net Income$132.33M-$42.25M$119.06M$225.46M7 Day Performance3.70%8.06%0.80%0.37%1 Month Performance20.27%8.71%5.65%3.57%1 Year Performance8.53%32.10%36.76%29.44% Voyager Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VYGRVoyager Therapeutics4.2048 of 5 stars$7.00+2.5%$17.43+149.0%+6.9%$381.71M$250.01M25.00100Upcoming EarningsAnalyst UpgradeADVMAdverum Biotechnologies3.8273 of 5 stars$7.98-1.2%$28.17+253.0%-18.8%$165.64M$3.60M-1.00190Short Interest ↑JNCEJounce TherapeuticsN/A$1.88-2.6%N/A+0.0%$98.94M$82M-0.73137Analyst ForecastHigh Trading VolumeCASICASI Pharmaceuticals3.1197 of 5 stars$6.50+11.5%$6.00-7.7%+23.3%$85.81M$33.88M-3.20180News CoveragePositive NewsGap DownBLUEbluebird bio2.8541 of 5 stars$0.48-4.0%$4.63+864.9%-84.1%$52.50M$54.90M-0.22323Upcoming EarningsAnalyst ForecastAGTCApplied Genetic Technologies0.0937 of 5 stars$0.39flatN/AN/A$26.62M$320,000.00-0.2783Analyst ForecastNews CoverageSPRYARS Pharmaceuticals2.8441 of 5 stars$14.77-4.1%$24.00+62.5%+328.7%$1.43B$30,000.00-31.4390SYRESpyre Therapeutics2.7206 of 5 stars$34.81+3.3%$46.43+33.4%N/A$1.40B$890,000.00-2.25100Positive NewsGap UpARDXArdelyx4.1613 of 5 stars$5.77-1.5%$11.67+102.2%+54.6%$1.34B$210.00M-21.37267Analyst ForecastInsider SellingOptions VolumeAnalyst RevisionGap UpKURAKura Oncology4.0437 of 5 stars$17.51-1.5%$28.83+64.7%+111.3%$1.34BN/A-7.85142Upcoming EarningsShort Interest ↓TVTXTravere Therapeutics2.1449 of 5 stars$17.53-3.1%$21.38+22.0%+161.5%$1.33B$177.64M-9.32460Earnings ReportAnalyst Forecast Related Companies and Tools Related Companies Adverum Biotechnologies Alternatives Jounce Therapeutics Alternatives CASI Pharmaceuticals Alternatives bluebird bio Alternatives Applied Genetic Technologies Alternatives ARS Pharmaceuticals Alternatives Spyre Therapeutics Alternatives Ardelyx Alternatives Kura Oncology Alternatives Travere Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VYGR) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyager Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
